Pharmaceutical News

RSS

A pill may provide hope to relapsed leukemia and lymphoma patients

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports published online today in Blood, the journal of the American Society of Hematology.

10 Mar 2014

Regado receives Fast Track designation from FDA for REG1

Regado Biosciences, Inc., a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program.

10 Mar 2014

FDA accepts Lundbeck's carbamazepine NDA for review

Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug (AED) carbamazepine. An action letter is anticipated before the end of 2014. Carbella is the proposed U.S. trade name for intravenous carbamazepine.

10 Mar 2014

ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award presented to Wakunaga

The American Botanical Council has presented its 2013 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award to Wakunaga Pharmaceutical Company, Ltd., of Osaka, Japan. Since its founding in 1955, the company has been committed to rigorous scientific and clinical research of its products, including its top-selling, clinically researched odorless Aged Garlic Extract¨.

10 Mar 2014

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

BerGenBio AS, an oncology biopharmaceutical company, is pleased to announce the award of a NOK 13 million grant from the Research Council of Norway's User-driven Research based Innovation programme (BIA) to help fund research into novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key driver of metastasis (cancer spread) and a mechanism of drug-resistance.

10 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg.

10 Mar 2014

Erlotinib has promising potential to improve treatment for cervical cancer

A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.

10 Mar 2014

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

In association with its 50th anniversary, the American Society of Clinical Oncology has named Dr. Daniel D. Von Hoff one of ASCO's 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care.

9 Mar 2014

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Researchers at the University of California, San Diego School of Medicine have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma. The finding was published in this week's online edition of Oncotarget.

8 Mar 2014

Teva launches generic Xeloda Tablets in the U.S.

Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Xeloda (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda is marketed by Genentech in the United States.

8 Mar 2014

Vitamin D boosts survival of breast cancer patients

Breast cancer patients with high levels of vitamin D in their blood are twice as likely to survive the disease as women with low levels of this nutrient, report University of California, San Diego School of Medicine researchers in the March issue of Anticancer Research.

7 Mar 2014

Researchers identify communication strategies aimed at creating risk perceptions about generic drugs

Although there is widespread consensus among the scientific community that the composition of generic drugs is identical to that of brand name drugs, this is not the case among the public.

7 Mar 2014

Prescriptions for benzodiazepines with opioid analgesics may lead to medication-related deaths

Prescriptions for benzodiazepines are rising in primary care, and their frequent combined use with opioid analgesics may be contributing to medication-related deaths, a finding that goes largely unreported, according to Stanford researchers.

7 Mar 2014

Study shows how changes in organized cell membrane network of heart muscle leads to heart failure

Colchicine, a drug that's used to treat gout, has the beneficial side effect of lowering the risk of heart attack in patients taking it. Conversely, taxol, a drug for treating cancer, has the opposite effect; raising the risk of heart failure.

6 Mar 2014

Scientists open door to development of new drugs to combat osteoporosis

Scientists from the University of Granada (UGR) have opened the door to the development of new drugs against osteoporosis, one of the most common chronic illnesses in the world, especially among women 65 or over.

6 Mar 2014

New drug is effective against superbug MRSA

"I routinely call hospitals and request their yearly antibiotic susceptibility testing data," said Washington University in St. Louis' Timothy Wencewicz. "The log might say, for example, that they've treated hundreds of patients for Acinetobacter baumanni, a bacterium brought into U.S. hospitals by soldiers wounded in the Iraq war, with 30 different antibiotics.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

Calcium and vitamin D supplements can improve cholesterol profiles in postmenopausal women

Calcium and vitamin D supplements after menopause can improve women's cholesterol profiles. And much of that effect is tied to raising vitamin D levels, finds a new study from the Women's Health Initiative just published online in Menopause, the journal of The North American Menopause Society.

6 Mar 2014

Bio-Rad announces release of beta version of the USP Spectral Library

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the release of beta version of USP Spectral Library™ powered by Bio Rad's KnowItAll® software technology platform for spectral analysis, identification, search, data management, and reporting.

From Bio-Rad Laboratories 5 Mar 2014

Pharmaceutical News

A pill may provide hope to relapsed leukemia and lymphoma patients

Regado receives Fast Track designation from FDA for REG1

FDA accepts Lundbeck's carbamazepine NDA for review

ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award presented to Wakunaga

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

Antares Pharma announces launch of OTREXUP to Dermatologists

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Erlotinib has promising potential to improve treatment for cervical cancer

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Teva launches generic Xeloda Tablets in the U.S.

Vitamin D boosts survival of breast cancer patients

Researchers identify communication strategies aimed at creating risk perceptions about generic drugs

Prescriptions for benzodiazepines with opioid analgesics may lead to medication-related deaths

Study shows how changes in organized cell membrane network of heart muscle leads to heart failure

Scientists open door to development of new drugs to combat osteoporosis

New drug is effective against superbug MRSA

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Calcium and vitamin D supplements can improve cholesterol profiles in postmenopausal women

Bio-Rad announces release of beta version of the USP Spectral Library

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News